Castle Biosciences

Fund: 2013, 2018
Sector: Life Sciences

Castle Biosciences is focused on developing and commercializing molecular diagnostics to aid health care professionals in assessing types and sub-types of tumors. Products focus on differentiating tumor types at the molecular level using various means of analyzing and comparing components of DNA.

visit website

Cerebrotech Medical Systems

Fund: 2013, 2018
Sector: Life Sciences

Cerebrotech Medical Systems has developed a non-invasive, continuous monitor for early detection of cerebral fluid change (primarily edema or bleeding) that can occur in a number of neurologic conditions, including stroke, traumatic brain injury, post brain surgery, etc.

visit website

Clearside Biomedical

Fund: 2013
Sector: Life Sciences

Clearside Biomedical is an ophthalmic company specializing in the research, development and commercialization of therapeutic products delivered through a proprietary microinjection platform that targets the suprachoroidal space in the region of the eye.

visit website

Contego Medical

Fund: 2013
Sector: Life Sciences

Contego Medical has developed a platform based on the integration of an embolic protection filter and a treatment device into a single catheter. By offering embolic protection on the same catheter as a balloon or stent, patients are offered a safer procedure without adding time, complexity, or expense and physicians can perform the procedure in less time.

visit website

Diabetes Care Group

Fund: 2013
Sector: Life Sciences

Diabetes Care Group is a healthcare services firm focused on treating diabetes through a proprietary, proven clinical delivery model that aids patients in controlling A1c levels. It’s a Fee-for-Results model that uses subscription-based and results-based bonuses, which allow patients to take advantage of services, such as nutritional counseling, that are typically not reimbursable under most healthcare plans. Since its founding in 2009, DCG has been organizing ideas around bringing diabetes medical management together with intensive, focused diabetes education in one location.

visit website

Diagnovus

Fund: 2013
Sector: Life Sciences

Diagnovus is focused on developing and commercializing molecular diagnostics to aid health care professionals in assessing types and sub-types of tumors. Products focus on differentiating tumor types at the molecular level using various means of analyzing and comparing components of DNA. The Company was acquired by Aegis Sciences Corporation in January 2015.

visit website

G1 Therapeutics

Fund: 2013
Sector: Life Sciences

G1 Therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. The company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of first-in-class compounds and best-in-class drug candidates.

visit website

LineaGen

Fund: 2013
Sector: Life Sciences

LineaGen provides chromosomal microarray and next generation sequencing genetic testing for individuals with autism spectrum disorder and other post-natal developmental disorders.  Lineagen also provides both pre- and post-test genetic counseling to assess the impact of the results on the patient and other family members, as well as anticipatory guidance to physicians regarding potential clinical management changes.

visit website

Myomo

Fund: 2013
Sector: Life Sciences

Myomo is a medical device company that has developed a custom myoelectric elbow orthotic device, enabling individuals afflicted with stroke and other neuromuscular conditions to self-initiate and control movement of a partially paralyzed arm using their own muscle signals.

visit website

NeuroTronik

Fund: 2013
Sector: Life Sciences

NeuroTronik Limited is a medical device company focused on providing hemodynamic management of patients who are admitted with acute heart failure syndrome (“AHFS”). The NeuroTronik technology utilizes a patented intravascular electrode system capable of selectively stimulating parasympathetic and sympathetic nerves simultaneously or in a preferred cadence.

visit website

NuSirt

Fund: 2013
Sector: Life Sciences

NuSirt Sciences is a biotechnology company focused on developing products targeting metabolic diseases associated with over-nutrition such as: obesity, diabetes, and inflammatory stress.

visit website